Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imlifidase in severe anti-GBM antibody disease
NCT05679401Phase 3Terminated
- Sponsor
- Hansa Biopharma
- Start
- Dec 2022
- Primary completion
- Jun 2025
- Modality
- Therapeutic Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of imlifidase in anti-glomerular basement membrane disease, sponsored by Hansa Biopharma. Started Dec 2022; status: terminated.
02
Drugs
imlifidase
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on NCT05679401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05679401.